Critical Analysis: SWEDISH ORPHAN/S (OTCMKTS:SWTUY) & Fobi AI (OTCMKTS:FOBIF)

Profitability

This table compares SWEDISH ORPHAN/S and Fobi AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SWEDISH ORPHAN/S	25.75%	29.63%	18.74%
Fobi AI	N/A	N/A	N/A

Volatility & Risk

SWEDISH ORPHAN/S has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Fobi AI has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.

Earnings & Valuation

This table compares SWEDISH ORPHAN/S and Fobi AI”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SWEDISH ORPHAN/S	$763.19 million	8.71	$134.73 million	$0.50	48.76
Fobi AI	$1.51 million	5.13	-$9.44 million	($0.04)	-0.86

SWEDISH ORPHAN/S has higher revenue and earnings than Fobi AI. Fobi AI is trading at a lower price-to-earnings ratio than SWEDISH ORPHAN/S, indicating that it is currently the more affordable of the two stocks.

Summary

SWEDISH ORPHAN/S beats Fobi AI on 9 of the 9 factors compared between the two stocks.

About SWEDISH ORPHAN/S

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

About Fobi AI

Fobi AI Inc., together with its subsidiaries, operates as a technology and data intelligence company in North America and Europe. It provides software as a service; consulting and development services; and resells, refers, and licenses its products. The company also offers mobile wallet solutions, digital coupons, and customer insights solutions. It serves various industries, including the hospitality and tourism industries. The company was formerly known as Loop Insights Inc. Fobi AI Inc. is based in Vancouver, Canada.